Ot­su­ka, Lund­beck eye Alzheimer's in­di­ca­tion in FDA ad­comm for Rex­ul­ti la­bel ex­pan­sion

Ot­su­ka and Lund­beck’s br­ex­pipra­zole is get­ting a joint FDA ad­comm to po­ten­tial­ly ex­pand the men­tal health drug’s la­bel for the treat­ment of ag­i­ta­tion as­so­ci­at­ed with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.